Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

Endoscopy net sales were $678 million ... For the fourth quarter of 2024, Boston Scientific expects EPS to range between $0.64 and $0.66, compared to analyst expectations of $0.64.

Boston Scientific shares fell Wednesday as its third ... The MedSurg division, which includes endoscopy, urology, and neuromodulation devices, had a 10% revenue rise to $1.48 billion.

Boston Scientific has proven itself to be a fierce ... stents, electrophysiology, endoscopy, urology, neuromodulation, and other interventional cardiology and interventional oncology devices.

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...